OphthaFund

Profile

OphthaFund is a niche early-stage investor based in Charleston, South Carolina, co-founded by George Magrath, Tom Mather, and Andrea Marshall. The team harnesses over 50 years of combined experience, with a focus on ophthalmology and life sciences. They are notable for their ophthalmology-dominated professional network, including board-certified ophthalmologists and ocular oncologists. George Magrath has an extensive background in pharmaceutical services, while Tom Mather brings vast expertise as an oculoplastic surgeon. Andrea Marshall, with a background in corporate law and experience leading angel investment groups, contributes to the diverse team dynamic.

OphthaFund specializes in early-stage investments within the ophthalmic and broader life sciences sectors. They perform meticulous due diligence to ensure strategic investments in promising start-ups with strong market potential. Their investment focus spans across sectors such as pharmaceuticals and medtech, maintaining a geographical emphasis on the U.S. They target companies with the capability to address major eye diseases through innovative technologies. Although specific check sizes are not disclosed, their portfolio demonstrates active participation in seed and Series A investments.

OphthaFund's portfolio includes notable companies such as MCAL Therapeutics, Encore Pharmaceuticals, and ForwardVue Pharma. These companies focus on emerging therapeutics in the ophthalmology field. An example of their successful exits includes Encore Vision's acquisition for $465 million. The firm consistently leverages strategic partnerships and collaborations with startups to enable accelerated commercialization of ophthalmic innovations.